News | May 13, 2023
Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
The company has reported total income of Rs. 4467.35 crores during the quarter ended March 31, 2023
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
Launches Thalassemia Bal Sewa Yojana portal and releases standard treatment guidelines for sickle cell anemia disease
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
Subscribe To Our Newsletter & Stay Updated
